ROSEN, NATIONAL INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 06, 2025 8:40 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

Core Insights - Faruqi & Faruqi, LLP is investigating potential securities law violations at Avantor, Inc. following disappointing financial results [2][3] - Avantor reported a net loss of $712 million for Q3 2025, primarily due to a non-cash goodwill impairment charge of $785 million, alongside a -5% organic revenue growth [3][4] - The company's stock price dropped over 23%, falling from $15.08 to $11.58 per share after the announcement of the financial results [4] Company Performance - Avantor's Q3 2025 results included a net loss of $712 million, attributed mainly to a goodwill impairment charge [3] - The company experienced a -5% organic revenue growth, which was below the guidance provided earlier in August [3] Market Reaction - Following the announcement of the financial results, Avantor's stock price fell by $3.50 per share, representing a decline of more than 23% [4]

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake†or the "Company†) (NASDAQ: MLTX). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. On September 28, 2025, MoonLake disclosed the 1 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Cytokinetics, Inc. following a significant stock drop after the FDA extended the review period for its heart drug aficamten due to the company's failure to submit a Risk Evaluation and Mitigation Strategy (REMS) with its New Drug Application (NDA) [3][2]. Company Summary - Cytokinetics, Inc. (NASDAQ: CYTK) experienced a stock decline of $5.57, or 12.9%, closing at $37.35 per share on May 2, 2025, after the FDA's announcement regarding the extended review period for aficamten [3]. - The company admitted to initially filing its NDA without a REMS, despite prior discussions with the FDA about safety and risk mitigation [3]. Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. - The firm is encouraging investors who suffered losses in Cytokinetics to contact them to discuss their legal options [1][4].

Accessibility StatementSkip Navigation NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=175616&from=4 CLASS PERIOD: December 27, 2023 to May 6, 2025 ALLEGATIONS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). CONTACT: The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm Shareholders who purchased shares of LNTH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead p ...

Accessibility StatementSkip Navigation WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statemen ...

ROSEN, A LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 05, 2025 6:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), ...

Core Points - MoonLake Immunotherapeutics has announced an underwritten offering of 7,142,857 Class A ordinary shares at a price of $10.50 per share, aiming to raise approximately $75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on or about November 6, 2025, pending customary closing conditions [1]. - Leerink Partners is acting as the sole bookrunning manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used alongside existing cash and marketable securities to fund the research and development of sonelokimab and for general corporate purposes [2]. Group 3: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody, targeting inflammatory diseases with significant unmet needs [5]. - The company addresses conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis, which affect millions globally [5].